|Trial||Title||Study Record Detail||Phase||Sponsor/Collaborator|
|A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer||NCT01283373||Phase I||Genentech, Inc.|
|Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer||NCT01774071||Phase I /Phase II||Memorial Sloan Kettering Cancer Center/Genentech Inc|
The Anti-STEAP1 antibody-drug conjugate DSTP3086S / RG7450 is also known as MSTP2109A.
Last Editorial Review: August 12, 2015